MXPA01008612A - Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses. - Google Patents

Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.

Info

Publication number
MXPA01008612A
MXPA01008612A MXPA01008612A MXPA01008612A MXPA01008612A MX PA01008612 A MXPA01008612 A MX PA01008612A MX PA01008612 A MXPA01008612 A MX PA01008612A MX PA01008612 A MXPA01008612 A MX PA01008612A MX PA01008612 A MXPA01008612 A MX PA01008612A
Authority
MX
Mexico
Prior art keywords
epsilon
ige
epitopes
domains
antagonists
Prior art date
Application number
MXPA01008612A
Other languages
Spanish (es)
Inventor
Martin Friede
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of MXPA01008612A publication Critical patent/MXPA01008612A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Abstract

The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the Cepsilon3 or Cepsilon4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.
MXPA01008612A 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses. MXPA01008612A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine
PCT/EP2000/001456 WO2000050461A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
MXPA01008612A true MXPA01008612A (en) 2003-06-24

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008612A MXPA01008612A (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.

Country Status (18)

Country Link
EP (1) EP1155038A1 (en)
JP (1) JP2002537403A (en)
KR (1) KR20020007314A (en)
CN (1) CN1520423A (en)
AR (1) AR029619A1 (en)
AU (1) AU3281100A (en)
CA (1) CA2363641A1 (en)
CO (1) CO5231139A1 (en)
CZ (1) CZ20013081A3 (en)
HK (1) HK1043134A1 (en)
HU (1) HUP0105490A3 (en)
IL (1) IL145025A0 (en)
MX (1) MXPA01008612A (en)
NO (1) NO20014131L (en)
NZ (1) NZ513680A (en)
PL (1) PL350992A1 (en)
TR (1) TR200102493T2 (en)
WO (1) WO2000050461A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2206701A (en) * 1999-12-21 2001-07-03 Acambis Research Limited A reversible linkage technology for controlled conjugation
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
JP2003047482A (en) * 2001-05-22 2003-02-18 Pfizer Prod Inc IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
ES2335979T3 (en) 2001-09-14 2010-04-07 Cytos Biotechnology Ag IMMUNOSTIMULATOR CPG PACKAGING IN VIRUS SIMILAR PARTICLES: PREPARATION METHOD AND ITS USE.
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
KR101228376B1 (en) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 Hapten-carrier conjugates and uses thereof
DE60336902D1 (en) 2002-07-19 2011-06-09 Cytos Biotechnology Ag VACCINE COMPOSITIONS CONTAINING AMYLOID BETA 1-6 ANTIGENARRAYS
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2004224762B2 (en) 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
KR20070008578A (en) * 2004-02-02 2007-01-17 타녹스 인코퍼레이티드 Identification of novel ige epitopes
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US8137670B2 (en) 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
SG172696A1 (en) 2006-06-12 2011-07-28 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2013191166A1 (en) * 2012-06-18 2013-12-27 日本全薬工業株式会社 IgE PEPTIDE VACCINE
KR102031845B1 (en) * 2018-04-06 2019-10-15 주식회사 에스엘에스바이오 A novel epitope of immunoglobulin e, antibody binding thereto and a kit comprising above antibody for analysis of immunoglobulin e

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (en) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd Peptide having anti-allergic activity
ES2296839T3 (en) * 1991-08-14 2008-05-01 Genentech Inc. IMMUNOGLOBULIN VARIANTS FOR SPECIFIC FC-EPSILON RECEIVERS.
KR100584051B1 (en) * 1996-03-01 2006-05-30 노파르티스 아게 Peptide Immunogens for Vaccination against and Treatment of Allergy
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
CN1520423A (en) 2004-08-11
NO20014131D0 (en) 2001-08-24
AR029619A1 (en) 2003-07-10
EP1155038A1 (en) 2001-11-21
PL350992A1 (en) 2003-02-24
NO20014131L (en) 2001-10-02
HUP0105490A2 (en) 2002-04-29
WO2000050461A1 (en) 2000-08-31
HK1043134A1 (en) 2002-09-06
CO5231139A1 (en) 2002-12-27
CA2363641A1 (en) 2000-08-31
JP2002537403A (en) 2002-11-05
CZ20013081A3 (en) 2002-02-13
KR20020007314A (en) 2002-01-26
IL145025A0 (en) 2002-06-30
HUP0105490A3 (en) 2002-05-28
NZ513680A (en) 2001-09-28
TR200102493T2 (en) 2002-02-21
AU3281100A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
MXPA01008612A (en) Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
AU3651802A (en) Recombinant anti-cd30 antibodies and uses thereof
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
HUP0301789A2 (en) Recombinant anti-cd40 antibody and uses thereof
EP1408986A4 (en) Proteomimetic compounds and methods
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
SG145712A1 (en) Crystalline tumor necrosis factor receptor 2 polypeptides
BG110703A (en) Pharmaceutical composition comprising human antibodies that bind human tnf-alpha and application of this composition
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
NO20063787L (en) Therapeutic preparations
WO2003092624A3 (en) Use of heat shock proteins to enhance efficacy of antibody therapeutics
NO20063193L (en) Fused pyrrolocarbazoles and processes for their preparation
MXPA03011499A (en) Fce fusion proteins for treatment of allergy and asthma.
ATE235551T1 (en) LIGAND (TIE LIGAND-4) FROM TIE-2 RECEPTOR AND ITS USES
MXPA01008613A (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses.
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
WO2002026781A3 (en) Ige receptor antagonists
WO2004046096A3 (en) Novel ligands that are antagonists of raf receptors, process for preparing them and use thereof in human medicine and in cosmetics
WO2002034288A3 (en) Vaccine for treating allergy
WO2003092714A3 (en) Peptide variants of ige constrained by beta-lactam bond
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2004078130A3 (en) Posh interacting proteins and related methods
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
RU2003110183A (en) METHOD FOR TREATING MULTIPLE SCLEROSIS